-
-
-
-
-
-
-
atai Life Sciences (ATAI) Tops Q1 EPS by 1c
-
-
-
-
-
-
-
atai Life Sciences (ATAI) Misses Q2 EPS by 20c
-
-
-
-
-
-
-
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
-
-
-
-
-
-
-
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
-
-
-
-
-
-
-
atai Life Sciences (ATAI) Reports Positive Final Results from Phase 1 Trial of GRX-917
-
-
-
-
-
-
-
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
-
-
-
-
-
-
-
atai Life Sciences (ATAI) Tops Q3 EPS by 2c
-
1,197,344 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

